CTIC und NOVARTIS...fette Partnerschaft und vile $$$$$$..hier gehts heute ab!!! - 500 Beiträge pro Seite
eröffnet am 18.09.06 12:15:38 von
neuester Beitrag 10.10.06 14:38:23 von
neuester Beitrag 10.10.06 14:38:23 von
Beiträge: 50
ID: 1.082.749
ID: 1.082.749
Aufrufe heute: 0
Gesamt: 4.992
Gesamt: 4.992
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 3591 | |
| vor 1 Stunde | 2691 | |
| vor 46 Minuten | 1897 | |
| heute 13:20 | 1799 | |
| vor 55 Minuten | 1429 | |
| vor 46 Minuten | 1345 | |
| vor 1 Stunde | 1080 | |
| vor 1 Stunde | 980 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.719,16 | -0,19 | 193 | |||
| 2. | 2. | 138,94 | -1,28 | 101 | |||
| 3. | 7. | 6,6400 | -1,31 | 95 | |||
| 4. | 5. | 0,1795 | -2,71 | 72 | |||
| 5. | 8. | 3,7900 | +1,34 | 64 | |||
| 6. | 4. | 2.380,60 | +0,05 | 60 | |||
| 7. | 9. | 12,440 | +0,89 | 44 | |||
| 8. | 17. | 7,2950 | -0,14 | 36 |
Feedback
die Top News!!!!:eek:
war ja abzusehen nach den ganzen Insider Käufen der letzten Tage.....
Press Release Source: Cell Therapeutics, Inc.
Cell Therapeutics Inc. Announces Worldwide License and Co-Development Agreement for Development and Commercialization of XYOTAX(TM), an Investigational Agent for Treatment of Women with Non-small Cell Lung Cancer and Other Cancers
Monday September 18, 6:00 am ET
Deal Worth Up to $285 million Can Help Fuel Future Growth at CTI
SEATTLE, Sept. 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced an exclusive worldwide licensing agreement with Novartis for the development and commercialization of XYOTAX(TM) (poliglumex paclitaxel), an investigational agent in Phase III for the treatment of non-small cell lung cancer (NSCLC) and other cancers.
ADVERTISEMENT
Total product registration and sales milestones for XYOTAX under the agreement could reach as much as $270 million. Novartis has also agreed to make a $15 million equity investment in CTI. CTI will have the option of co- detailing XYOTAX in the United States under the direction of Novartis, under an agreement to be entered into if CTI exercises the option. The closing of the transaction is subject to antitrust regulatory clearance and certain other closing conditions.
XYOTAX(TM) (Zi-o-taks) is a biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable polyglutamate polymer, resulting in a new chemical entity. The investigational medicine is currently in phase III clinical trials to test whether single agent XYOTAX(TM) provides improved overall survival compared to paclitaxel in women with NSCLC and poor performance status.
The agreement also provides Novartis with an option to develop and commercialize pixantrone based on agreed terms. Pixantrone is an investigational agent designed to potentially increase anti-tumor activity and decrease the potential for cardiac toxicity associated with the currently marketed anthracyclines. If Novartis exercises its option on pixantrone under certain conditions, Novartis would pay CTI a $7.5M fee and up to $104M in registration and sales related milestones.
"This agreement brings the strength of one of the most innovative leaders in oncology to the development and commercialization of XYOTAX, an agent that could be demonstrated in ongoing trials to prolong survival in women with lung cancer and potentially become the first gender specific therapy for this disease," said James A. Bianco, M.D., President and CEO of CTI. "It also provides pixantrone with potential access to a market leader in blood related cancer therapeutics to fully maximize its commercial potential."
Bianco added: "This collaboration takes CTI one step closer to rebuilding its commercial presence in the United States and its goal of becoming a profitable cancer focused company. It also allows us to continue our growth through an acquisition strategy looking for other novel targeted agents to add to our development pipeline and into our future commercial infrastructure."
CTI had also announced in June that they have agreed on pathways for regulatory approvals for XYOTAX in recent meetings with the U.S. Food and Drug Administration (FDA) and the European Medicine Agency's Scientific Advice Working Party (SAWP). Lung cancer continues to be a major killer of men and women on both continents. In the United States, lung cancer is now the number one cancer killer of women.
The common stock to be issued to Novartis has not been registered under the Securities Act of 1933, as amended, or any state securities laws. The common stock may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933, as amended, and any applicable state laws. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of this common stock. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
About XYOTAX
XYOTAX(TM) (paclitaxel poliglumex) is a biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that XYOTAX is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that XYOTAX metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies.
About Pixantrone
Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplified administration compared to the currently marketed anthracyclines.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.cticseattle.com.
Conference Call
A conference call will be held on September 18, 2006 at 8:30 am (ET) to discuss the agreement. The domestic call-in number is 1-800-240-7305 and the international number is 1-303-205-0033. The call will be webcast live and archived after the call for replay and may include forward-looking information.
This press release includes and the conference call may include forward- looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. These forward looking statements include statements regarding the conditions to effectiveness of the agreements being satisfied, the achievement of any product registration and sales milestones under the agreement and the amount of any such milestones, the development and commercialization of XYOTAX and pixantrone and CTI's future operations and plans. The risks and uncertainties that could affect the achievement or amount of any product registration and sales milestones include risks associated with Novartis choosing to exercise its rights under the license agreement, the achievement of the product and sales milestones set forth in the license agreement and Novartis' ability to terminate the license agreement. The risks and uncertainties that could affect the development of XYOTAX and pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with XYOTAX and pixantrone in particular including, without limitation, the potential failure of XYOTAX to prove safe and effective for treatment of lung and ovarian cancers and pixantrone to prove safe and effective for treatment of non-Hodgkin's lymphoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling XYOTAX and pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
--------------------------------------------------------------------------------
war ja abzusehen nach den ganzen Insider Käufen der letzten Tage.....
Press Release Source: Cell Therapeutics, Inc.
Cell Therapeutics Inc. Announces Worldwide License and Co-Development Agreement for Development and Commercialization of XYOTAX(TM), an Investigational Agent for Treatment of Women with Non-small Cell Lung Cancer and Other Cancers
Monday September 18, 6:00 am ET
Deal Worth Up to $285 million Can Help Fuel Future Growth at CTI
SEATTLE, Sept. 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced an exclusive worldwide licensing agreement with Novartis for the development and commercialization of XYOTAX(TM) (poliglumex paclitaxel), an investigational agent in Phase III for the treatment of non-small cell lung cancer (NSCLC) and other cancers.
ADVERTISEMENT
Total product registration and sales milestones for XYOTAX under the agreement could reach as much as $270 million. Novartis has also agreed to make a $15 million equity investment in CTI. CTI will have the option of co- detailing XYOTAX in the United States under the direction of Novartis, under an agreement to be entered into if CTI exercises the option. The closing of the transaction is subject to antitrust regulatory clearance and certain other closing conditions.
XYOTAX(TM) (Zi-o-taks) is a biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable polyglutamate polymer, resulting in a new chemical entity. The investigational medicine is currently in phase III clinical trials to test whether single agent XYOTAX(TM) provides improved overall survival compared to paclitaxel in women with NSCLC and poor performance status.
The agreement also provides Novartis with an option to develop and commercialize pixantrone based on agreed terms. Pixantrone is an investigational agent designed to potentially increase anti-tumor activity and decrease the potential for cardiac toxicity associated with the currently marketed anthracyclines. If Novartis exercises its option on pixantrone under certain conditions, Novartis would pay CTI a $7.5M fee and up to $104M in registration and sales related milestones.
"This agreement brings the strength of one of the most innovative leaders in oncology to the development and commercialization of XYOTAX, an agent that could be demonstrated in ongoing trials to prolong survival in women with lung cancer and potentially become the first gender specific therapy for this disease," said James A. Bianco, M.D., President and CEO of CTI. "It also provides pixantrone with potential access to a market leader in blood related cancer therapeutics to fully maximize its commercial potential."
Bianco added: "This collaboration takes CTI one step closer to rebuilding its commercial presence in the United States and its goal of becoming a profitable cancer focused company. It also allows us to continue our growth through an acquisition strategy looking for other novel targeted agents to add to our development pipeline and into our future commercial infrastructure."
CTI had also announced in June that they have agreed on pathways for regulatory approvals for XYOTAX in recent meetings with the U.S. Food and Drug Administration (FDA) and the European Medicine Agency's Scientific Advice Working Party (SAWP). Lung cancer continues to be a major killer of men and women on both continents. In the United States, lung cancer is now the number one cancer killer of women.
The common stock to be issued to Novartis has not been registered under the Securities Act of 1933, as amended, or any state securities laws. The common stock may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933, as amended, and any applicable state laws. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of this common stock. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
About XYOTAX
XYOTAX(TM) (paclitaxel poliglumex) is a biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that XYOTAX is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that XYOTAX metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies.
About Pixantrone
Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplified administration compared to the currently marketed anthracyclines.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.cticseattle.com.
Conference Call
A conference call will be held on September 18, 2006 at 8:30 am (ET) to discuss the agreement. The domestic call-in number is 1-800-240-7305 and the international number is 1-303-205-0033. The call will be webcast live and archived after the call for replay and may include forward-looking information.
This press release includes and the conference call may include forward- looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. These forward looking statements include statements regarding the conditions to effectiveness of the agreements being satisfied, the achievement of any product registration and sales milestones under the agreement and the amount of any such milestones, the development and commercialization of XYOTAX and pixantrone and CTI's future operations and plans. The risks and uncertainties that could affect the achievement or amount of any product registration and sales milestones include risks associated with Novartis choosing to exercise its rights under the license agreement, the achievement of the product and sales milestones set forth in the license agreement and Novartis' ability to terminate the license agreement. The risks and uncertainties that could affect the development of XYOTAX and pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with XYOTAX and pixantrone in particular including, without limitation, the potential failure of XYOTAX to prove safe and effective for treatment of lung and ovarian cancers and pixantrone to prove safe and effective for treatment of non-Hodgkin's lymphoma, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling XYOTAX and pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 8-K, and 10-Q. CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
--------------------------------------------------------------------------------
Antwort auf Beitrag Nr.: 24.016.978 von Irishkiller am 18.09.06 12:15:38
Cell Therapeutics, Novartis in agreement on Xyotax
LONDON (MarketWatch) -- Cell Therapeutics, Inc. (CTIC : Cell Therapeutics Inc
Last: 1.95+0.01+0.52%
4CTIC1.95, +0.01, +0.5%) has signed a licensing and co-development agreement with Novartis (NVS
NVS57.06, -0.05, -0.1%) for Xyotax, a lung-cancer drug. under the deal, Cell Therapeutics could receive up to $270 million depending on sales milestones. Novartis has also agreed to make a $15 million equity investment in Cell Therapeutics.
LONDON (MarketWatch) -- Cell Therapeutics, Inc. (CTIC : Cell Therapeutics Inc
Last: 1.95+0.01+0.52%
4CTIC1.95, +0.01, +0.5%) has signed a licensing and co-development agreement with Novartis (NVS
NVS57.06, -0.05, -0.1%) for Xyotax, a lung-cancer drug. under the deal, Cell Therapeutics could receive up to $270 million depending on sales milestones. Novartis has also agreed to make a $15 million equity investment in Cell Therapeutics.
strong buy!!!!!
Antwort auf Beitrag Nr.: 24.017.087 von Irishkiller am 18.09.06 12:23:22Stuttgart auf 1,70 hochgetaxt,,,,
und an den anderen börsen werden zum Zeitpunkt keine bid/ask kurse gestellt.....
hihi...was das wohl zu bedeuten hat.....
und an den anderen börsen werden zum Zeitpunkt keine bid/ask kurse gestellt.....
hihi...was das wohl zu bedeuten hat.....
Trading Spotlight
IN D vom Handel ausgesetzt!!!!!!!!!!!!!!!!!!!!!!!!!!!!
bid in USA bei 2,20.....sicher gleich noch weiter steigend.....
hehehe..wie weit wird das Teil heute laufen???
Wer wagt eine Prognose??
.....sicher gleich noch weiter steigend.....hehehe..wie weit wird das Teil heute laufen???
Wer wagt eine Prognose??
8.30 Uhr Conference Call,da gibt es sicher Details des Deals.....
Antwort auf Beitrag Nr.: 24.018.188 von Irishkiller am 18.09.06 13:44:21steigt weiter....2,22
Antwort auf Beitrag Nr.: 24.018.249 von Irishkiller am 18.09.06 13:47:212,52
WANN KAM DIE NEWS RAUS?
Antwort auf Beitrag Nr.: 24.019.139 von dv7950 am 18.09.06 14:40:48kann bitte jemand die nachricht kurz zusammen fassen auf deutsch ... ?
danke !
danke !
Handel wieder aufgenommen und bin dabei.
Die Schweizer Novartis hat mit den US-Amerikanern ein weltweites exklusives Lizenzabkommen zur Entwicklung und Vermarktung des Produktkandidaten Xyotax (poliglumex paclitaxel) geschlossen. Der Wirkstoff stecke derzeit in der Phase III der klinischen Entwicklung für nicht-kleinzelligen Lungenkrebs (NSCLC) und andere Krebsarten, teilte Cell Therapeutics mit. Für die Produktregistrierung und das Erreichen von Meilensteinen könnte Cell Zahlungen von bis zu 270 Millionen Dollar erhalten. Zudem habe sich Novartis bereit erklärt, 15 Millionen Dollar in das Aktienkapital von Cell zu investieren./fat/ck
Geld: 1,76 1.500 Stk.
Brief: 1,90 1.500 Stk.
Taxierungszeitpunkt 18.09.2006 15:09:43 Uhr
Brief: 1,90 1.500 Stk.
Taxierungszeitpunkt 18.09.2006 15:09:43 Uhr
Geld: 1,73 1.000 Stk.
Brief: 1,86 3.000 Stk.
Taxierungszeitpunkt 18.09.2006 15:15:23 Uhr
Deutschland
Brief: 1,86 3.000 Stk.
Taxierungszeitpunkt 18.09.2006 15:15:23 Uhr
Deutschland
Antwort auf Beitrag Nr.: 24.019.591 von eidman am 18.09.06 15:08:50DANKE !
das klingt natürlich super hier sollte in den nächsten tagen einiges an potenzial drin sein ...
das klingt natürlich super
hier sollte in den nächsten tagen einiges an potenzial drin sein ...
warum geschieht in FFM nichts??? Ich habe auch orders aufgegeben, aber es gibt keine Kurse???
Antwort auf Beitrag Nr.: 24.019.980 von pascal12 am 18.09.06 15:27:22Kauf in Stuttgart oder US
sind da nicht die Gebühren wesentlich höher?
In DE war in FFm immer der höchste Umsatz bisher...
In DE war in FFm immer der höchste Umsatz bisher...
RT Nasdaq
2,42
2,42
Antwort auf Beitrag Nr.: 24.020.075 von pascal12 am 18.09.06 15:31:37Deine Gebühren hättest Du jetzt schon wieder drin
wow....schon 3,5 millionen gehandelt...und nebenbei tageshoch bei 2,53!!!!
rock on!
rock on!
du meinst 1,53euro.
was hats Euch so gekostet? ich habe jetzt in FFM für 1,88Euro bekommen (zum Glück hatte ich schon vorher Stücke zu 1,07)
Antwort auf Beitrag Nr.: 24.020.577 von pascal12 am 18.09.06 15:53:14..für diese Wahnsinnsnachricht hätte ich eigentlich auf noch mehr bums gehofft..
Naja , ist ja im Vorfeld schon schön gestiegen..
Vieleicht erreiche ich meinen einstandpreis von 2,8€ dieses Jahr noch
Naja , ist ja im Vorfeld schon schön gestiegen..
Vieleicht erreiche ich meinen einstandpreis von 2,8€ dieses Jahr noch
vor ca 1 Monat, als die Testergebnisse herauskammen, sind sie mehr gestiegen. Heute haben sie schon viel wieder von den Gewinnen eingebüßt. aber bei 2,50USD hocken noch viele ehemalige Käufer - dass wird eine schwierige Marke. Aber wenn die Zulassung kommt fällt eh jede Marke
in München bid - ask 1,55 zu 1,60 heißt, dass da bietet jemand Aktien für 1,60€ an oder was bedeutet dieses bid - ask immer?
Antwort auf Beitrag Nr.: 24.022.300 von wallstreetcrash am 18.09.06 17:12:35sehe ich genauso..hatte auch einen grösseren Anstieg erwartet!
Aber wie Du schreibst,die Aktie ist im Vorfeld schon beachtlich gestiegen,wahrscheinlich dahe einige Gewinnmitnahmen..
Umsätze heute phenomenal,auch das lässt auf weitere steigende Kurse hoffen!
Bin gespannt,wie es morgen weiter geht,hält der Uptrend an,bin ich weiterhin sehr sehr zuversichtlich.
Mein Einstiegskurs liegt auch höher,immerhin 5000 Stück zu 2,83 Euro,hoffe-und bin optimistisch-den auch recht bald wiederzusehen,,,,
Werde sicher auch weiter halten,ähnliches Szenario hatte ich mal bei Elan,auch viel zu füh verkauft,und dann an der Aussenlinie zugesehen,wie das Teil von 3 bis knapp 20 Dollar lief!!!
Meiner Meinung nach ist die heutige PR ein Indiz dafür,dass wir sehr wahrscheinlich im kommenden Jahr(Mitte??) die Zulassung für Xyotax sehen werden,steigende Kurse im Vorfeld sind zu erwarten,,,,
viel Glück allen!!!
Aber wie Du schreibst,die Aktie ist im Vorfeld schon beachtlich gestiegen,wahrscheinlich dahe einige Gewinnmitnahmen..
Umsätze heute phenomenal,auch das lässt auf weitere steigende Kurse hoffen!
Bin gespannt,wie es morgen weiter geht,hält der Uptrend an,bin ich weiterhin sehr sehr zuversichtlich.
Mein Einstiegskurs liegt auch höher,immerhin 5000 Stück zu 2,83 Euro,hoffe-und bin optimistisch-den auch recht bald wiederzusehen,,,,
Werde sicher auch weiter halten,ähnliches Szenario hatte ich mal bei Elan,auch viel zu füh verkauft,und dann an der Aussenlinie zugesehen,wie das Teil von 3 bis knapp 20 Dollar lief!!!
Meiner Meinung nach ist die heutige PR ein Indiz dafür,dass wir sehr wahrscheinlich im kommenden Jahr(Mitte??) die Zulassung für Xyotax sehen werden,steigende Kurse im Vorfeld sind zu erwarten,,,,
viel Glück allen!!!
Antwort auf Beitrag Nr.: 24.031.230 von Irishkiller am 18.09.06 23:14:53Der Aktionär meinte, die Zulassung für Europa wohl schon diesen Herbst und in den Staaten nächstes Jahr
Antwort auf Beitrag Nr.: 24.034.420 von pascal12 am 19.09.06 08:18:02stimmt,
ähnliches habe ich in irgendeinem US-Aktienforum auch gelesen....
dann könnte ja der Uptrend-alleine spekulierend auf diese News-weiterhin anhalten....
time will tell,,,
ähnliches habe ich in irgendeinem US-Aktienforum auch gelesen....
dann könnte ja der Uptrend-alleine spekulierend auf diese News-weiterhin anhalten....
time will tell,,,
yahoo board:
Next stop, interim pixantrone data Q1/07 and interim xyotax data Q2/07, with potential approval for xyotax by Q4/07 or (more likely, IMO) Q1/08.
noch ein weiter Weg vor uns......
Next stop, interim pixantrone data Q1/07 and interim xyotax data Q2/07, with potential approval for xyotax by Q4/07 or (more likely, IMO) Q1/08.
noch ein weiter Weg vor uns......
ist dass eine offizielle Nachricht? Auf der Ctic-Homepage steht nichts davon
nein,
wie geschrieben aus dem Yahoo Message Board.....
wie geschrieben aus dem Yahoo Message Board.....
aber das ist offiziell:::
News:
Press Release Source: Cell Therapeutics, Inc.
Cell Therapeutics, Inc. to Present at UBS Global Life Sciences Conference
Tuesday September 19, 7:00 am ET
SEATTLE, Sept. 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) management will present at the UBS 2006 Global Life Sciences Conference on Wednesday, September 27 at 4:00 pm (ET).
The conference will be held September 25-28, 2006, at the Grant Hyatt Hotel in New York City. The presentation will be audio webcast live and available for replay approximately three hours after the presentation ends. The webcast can be accessed on the CTI web site at www.cticseattle.com.
UBS 2006 Global Life Sciences Conference
CTI Presentation: Wednesday, September 27
4:00 p.m. ET/1:00 p.m. PT/10:00 p.m. CET
Audio webcast at www.cticseattle.com
News:
Press Release Source: Cell Therapeutics, Inc.
Cell Therapeutics, Inc. to Present at UBS Global Life Sciences Conference
Tuesday September 19, 7:00 am ET
SEATTLE, Sept. 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) management will present at the UBS 2006 Global Life Sciences Conference on Wednesday, September 27 at 4:00 pm (ET).
The conference will be held September 25-28, 2006, at the Grant Hyatt Hotel in New York City. The presentation will be audio webcast live and available for replay approximately three hours after the presentation ends. The webcast can be accessed on the CTI web site at www.cticseattle.com.
UBS 2006 Global Life Sciences Conference
CTI Presentation: Wednesday, September 27
4:00 p.m. ET/1:00 p.m. PT/10:00 p.m. CET
Audio webcast at www.cticseattle.com
Antwort auf Beitrag Nr.: 24.040.850 von Irishkiller am 19.09.06 14:15:52und der daraus resultierende Anstieg des Aktienkurses auch.....
bid bei 2,15!Immerhin..gute 10% plus...
rock on!
bid bei 2,15!Immerhin..gute 10% plus...
rock on!
wo und wie erfährt man den von einer eventuellen Zulassung durch die FDA? Oder wird man davon immer überrascht?
wieso steigt der Kurs nach Bekanntgabe, dass sie bei einer Präsentation dabei sind?
mehr News.....
Press Release Source: Cell Therapeutics, Inc.
Cell Therapeutics Inc. Announces Registered Offering of $40 Million in Common Stock
Tuesday September 19, 8:22 am ET
SEATTLE, Sept. 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) today announced that it has agreed to sell approximately 23,121,387 shares of its common stock at a per share price of $1.73 per share in a registered offering. CTI has also granted the purchasing investors a 90-day option to purchase approximately an additional 5,780,346 shares at the same price per share.
ADVERTISEMENT
The offering is expected to close on or about September 21, 2006, subject to certain closing conditions.
Rodman & Renshaw, LLC acted as the lead placement agent and sole book runner on this transaction. Punk, Ziegel and Company acted as the co-placement agent.
A shelf registration statement relating to the common stock to be issued in the offering has been filed with the Securities and Exchange Commission and has become effective. A prospectus supplement related to the offering will be filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our common stock. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. The risks and uncertainties include the risk that the above described transaction will not close as a result of the failure to meet closing conditions, investors may breach or withdraw their commitment, and until closed there is no assurance that it will close or what the total amount may be, and other risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K and 8-K. CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
--------------------------------------------------------------------------------
Source: Cell Therapeutics, Inc.
Press Release Source: Cell Therapeutics, Inc.
Cell Therapeutics Inc. Announces Registered Offering of $40 Million in Common Stock
Tuesday September 19, 8:22 am ET
SEATTLE, Sept. 19 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) today announced that it has agreed to sell approximately 23,121,387 shares of its common stock at a per share price of $1.73 per share in a registered offering. CTI has also granted the purchasing investors a 90-day option to purchase approximately an additional 5,780,346 shares at the same price per share.
ADVERTISEMENT
The offering is expected to close on or about September 21, 2006, subject to certain closing conditions.
Rodman & Renshaw, LLC acted as the lead placement agent and sole book runner on this transaction. Punk, Ziegel and Company acted as the co-placement agent.
A shelf registration statement relating to the common stock to be issued in the offering has been filed with the Securities and Exchange Commission and has become effective. A prospectus supplement related to the offering will be filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our common stock. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. The risks and uncertainties include the risk that the above described transaction will not close as a result of the failure to meet closing conditions, investors may breach or withdraw their commitment, and until closed there is no assurance that it will close or what the total amount may be, and other risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K and 8-K. CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
--------------------------------------------------------------------------------
Source: Cell Therapeutics, Inc.
was bedeutet den dieser Mist? Die Kurse rasen runter...
Antwort auf Beitrag Nr.: 24.041.055 von Irishkiller am 19.09.06 14:26:32...und daraus resultierende Abschläge.....shit...so schnell kann's gehen
1.95 0 (0.00) 0 1.78 (20) + 1.79 (100) 2,105,986
1.95 0 (0.00) 0 1.78 (20) + 1.79 (100) 2,105,986
sowas ist für mich der allerletzte dreck
kaum gibts mal eine gute news, wird solcher schrott sofort abverkauft per plazierung an der börse und die aktienpresse sofort angeschmissen
strong sell
mir kommt das kotzen bei solchen werten
kaum gibts mal eine gute news, wird solcher schrott sofort abverkauft per plazierung an der börse und die aktienpresse sofort angeschmissen
strong sell
mir kommt das kotzen bei solchen werten
aber das dürfte keine langfristige Auswirkung haben, oder?
Antwort auf Beitrag Nr.: 24.042.237 von DMKE am 19.09.06 15:23:41locker bleiben.....gibt ja anscheinend auch genügend Käufer....
in einem Jahr lachen wir über die momentanen Kurse
in einem Jahr lachen wir über die momentanen Kurse
Abverkauf geht weiter
heute endet doch der zeitliche Rahmen für diese Verkaufsaktion.
Dann steht ab morgen Kursen von über 1,73$ nichts im Wege...
Dann steht ab morgen Kursen von über 1,73$ nichts im Wege...
Cell Therapeutics Inc. Completes Registered Offering of $40 Million in Common Stock
Tuesday September 26, 7:00 am ET
SEATTLE, Sept. 26 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced that it had completed the previously announced sale of 23,121,394 shares of its common stock at a per share price of $1.73 per share in a registered offering. CTI has also granted the purchasing investors a 90-day option to purchase an additional 5,780,352 shares at the same price per share.
ADVERTISEMENT
Rodman & Renshaw, LLC acted as the lead placement agent and sole book runner on this transaction. Punk, Ziegel and Company acted as the co-placement agent.
A shelf registration statement relating to the common stock issued in the offering has been filed with the Securities and Exchange Commission and has become effective. A prospectus supplement related to the offering has been filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our common stock. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
--------------------------------------------------------------------------------
Source: Cell Therapeutics, Inc.
Tuesday September 26, 7:00 am ET
SEATTLE, Sept. 26 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced that it had completed the previously announced sale of 23,121,394 shares of its common stock at a per share price of $1.73 per share in a registered offering. CTI has also granted the purchasing investors a 90-day option to purchase an additional 5,780,352 shares at the same price per share.
ADVERTISEMENT
Rodman & Renshaw, LLC acted as the lead placement agent and sole book runner on this transaction. Punk, Ziegel and Company acted as the co-placement agent.
A shelf registration statement relating to the common stock issued in the offering has been filed with the Securities and Exchange Commission and has become effective. A prospectus supplement related to the offering has been filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our common stock. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
--------------------------------------------------------------------------------
Source: Cell Therapeutics, Inc.
endloch scheint sich wiedr was zu tun. NY vorbörslich 7% im Plus.
Aber es gibt keine Nachrichten?!?
Aber es gibt keine Nachrichten?!?
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 193 | ||
| 101 | ||
| 95 | ||
| 72 | ||
| 64 | ||
| 60 | ||
| 44 | ||
| 36 | ||
| 36 | ||
| 32 |
| Wertpapier | Beiträge | |
|---|---|---|
| 30 | ||
| 30 | ||
| 29 | ||
| 26 | ||
| 25 | ||
| 23 | ||
| 20 | ||
| 20 | ||
| 20 | ||
| 18 |
